Company Quick10K Filing
Omnicell
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 43 $3,703
10-K 2020-02-26 Annual: 2019-12-31
10-Q 2019-11-01 Quarter: 2019-09-30
10-Q 2019-08-02 Quarter: 2019-06-30
10-Q 2019-05-03 Quarter: 2019-03-31
10-K 2019-02-27 Annual: 2018-12-31
10-Q 2018-11-02 Quarter: 2018-09-30
10-Q 2018-08-03 Quarter: 2018-06-30
10-Q 2018-05-04 Quarter: 2018-03-31
10-K 2018-02-27 Annual: 2017-12-31
10-Q 2017-11-03 Quarter: 2017-09-30
10-Q 2017-08-04 Quarter: 2017-06-30
10-Q 2017-05-05 Quarter: 2017-03-31
10-K 2017-02-28 Annual: 2016-12-31
10-Q 2016-11-07 Quarter: 2016-09-30
10-Q 2016-08-05 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-02-26 Annual: 2015-12-31
10-Q 2015-11-06 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-08 Quarter: 2015-03-31
10-K 2015-03-30 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-08-07 Quarter: 2014-06-30
10-Q 2014-05-12 Quarter: 2014-03-31
10-K 2014-03-17 Annual: 2013-12-31
10-Q 2013-11-08 Quarter: 2013-09-30
10-Q 2013-08-09 Quarter: 2013-06-30
10-Q 2013-05-09 Quarter: 2013-03-31
10-K 2013-03-11 Annual: 2012-12-31
10-Q 2012-11-09 Quarter: 2012-09-30
10-Q 2012-08-09 Quarter: 2012-06-30
10-Q 2012-05-08 Quarter: 2012-03-31
10-K 2012-03-08 Annual: 2011-12-31
10-Q 2011-11-04 Quarter: 2011-09-30
10-Q 2011-08-05 Quarter: 2011-06-30
10-Q 2011-05-10 Quarter: 2011-03-31
10-K 2011-03-11 Annual: 2010-12-31
10-Q 2010-11-08 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-05-10 Quarter: 2010-03-31
10-K 2010-02-24 Annual: 2009-12-31
8-K 2020-02-13 Officers, Exhibits
8-K 2020-02-12 Other Events
8-K 2020-02-06 Earnings, Exhibits
8-K 2019-12-05 Other Events
8-K 2019-11-15 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-10-24 Earnings, Exhibits
8-K 2019-07-25 Earnings, Exhibits
8-K 2019-05-14 Shareholder Vote
8-K 2019-04-25 Earnings, Exhibits
8-K 2019-03-05 Officers, Exhibits
8-K 2019-02-19 Officers, Exhibits
8-K 2019-02-07 Earnings, Exhibits
8-K 2018-10-25 Earnings, Exhibits
8-K 2018-09-13 Officers, Exhibits
8-K 2018-07-26 Earnings, Exhibits
8-K 2018-06-05 Officers, Exhibits
8-K 2018-05-15 Shareholder Vote
8-K 2018-04-26 Earnings, Exhibits
8-K 2018-03-01 Officers
8-K 2018-02-08 Officers
8-K 2018-02-02 Officers
8-K 2018-02-01 Earnings, Exhibits

Omnicell Financials

OMCL Metrics, Comps, Filings

Annual | Quarterly

Business

We are a leading provider of medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions. Our product offerings help enable healthcare providers improve patient safety, increase efficiency, lower costs, tighten regulatory compliance, and address population health challenges. Delivering on our vision of improving healthcare for everyone, our recently introduced products, robotic XR2 Automated Central Pharmacy System and IVX Workflow, are helping customers move closer to a fully automated pharmacy by replacing manual, error-prone processes with automated workflows. In addition, our analytics software and service offerings, such as Omnicell Performance Center™, are helping our customers harness the power of data and deliver business intelligent insights.

Through our medication management platform that spans the continuum of care, we are developing a vision for a fully automated infrastructure that supports improved patient care, fewer errors, enhanced safety, and new opportunities for growth. With our vision of the Autonomous Pharmacy, we are seeking to lead a transformation of medication management. By delivering more advanced automation, data intelligence, and managed services, to be powered by a cloud data platform, we believe we will help empower healthcare and pharmacy providers to focus on the clinical tasks. We plan to build out our vision of the Autonomous Pharmacy on cloud infrastructure, to help enable more nimble innovation and greater digital connectivity across our systems.

We believe our broad portfolio and roadmap align us with the long-term trends of the healthcare market to manage patients across the continuum of care while helping to control costs and improve patient outcomes.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Apple (AAPL) 1,017,275 38% 12.5 16% 338,516 248,028 260,174 98,392 55,256 85,615 1,068,730
IBM (IBM) 127,843 47% 11.3 5% 149,620 131,524 77,131 36,076 7,712 16,000 181,130
HP (HPQ) 28,057 19% 8.8 9% 33,467 58,756 11,170 3,152 3,267 28,671
Hewlett Packard (HPE) 19,466 8% 6.1 2% 51,803 34,705 29,135 2,393 1,049 4,088 24,784
Nice (NICE) 6,628 0% 3,207 1,191 0 0 0 0 6,601
Blackbaud (BLKB) 4,435 54% 46.0 1% 1,710 1,329 884 479 20 101 4,668
Perspecta (PRSP) 4,224 18% 9.8 1% 6,319 4,156 4,448 807 79 672 6,619
51job (JOBS) 3,731 0% 12,238 4,420 0 0 0 0 1,757
Omnicell (OMCL) 3,062 48% 32.8 3% 1,244 437 649 313 39 91 3,002
John Bean Technologies (JBT) 3,238 30% 25.8 7% 1,919 1,395 1,938 589 130 153 3,957
Rexnord (RXN) 3,539 39% 11.8 5% 3,311 1,990 2,052 796 176 382 4,499
Q2 Holdings (QTWO) 3,793 48% -60.4 -7% 978 596 300 143 -67 -53 3,190
LogMeIn (LOGM) 3,619 75% 14.6 0% 3,859 1,084 1,248 935 15 254 3,698
Huami (HMI) 2,181 0% 3,258 1,449 0 0 0 0 729
Cray (CRAY) 1,447 29% -13.5 -23% 460 183 396 115 -108 -95 1,282
Fitbit (FIT) 991 35% -5.4 -13% 1,377 788 1,504 523 -185 -131 704
One Stop Systems (OSS) 49 32% -111.5 -5% 38 10 40 13 -2 -0 48
Socket Mobile (SCKT) 15 52% 19.7 1% 19 6 15 8 0 1 14
Dell Technologies (DELL)

Balance Sheet ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash1926210512682543267
Accounts Receivable37555983108150189196
Inventory18273132476996101
PP&E1734763632424352
Assets3624424935605799359801,081
Accounts Payable1118161923274838
Long-Term Debt254210135
Liabilities79134144170176503463402
Stockholders' Equity283308349390402432517680
Income Statement ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue60667336096693716787
Cost of Revenue303132207387689415
Gross Profit136171203234248314322372
R&D2224292835586665
SG&A98120139156168250250263
Tax6117912118-2
Net Income1624313112138
Cash Flow ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating31395565344825104
Cash Investing-13-169-20-43-46-341-35-54
Cash Financing-2-07-0-32266-10-14